不同化疗方案治疗晚期非小细胞肺癌的临床疗效及肿瘤标志物与疗效的相关性

 目的 探讨不同化疗方案治疗晚期非小细胞肺癌(non small cell lung cancer,NSCLC)的临床疗效及肿瘤标志物与疗效的相关性。方法 选取2015-01至2017-06北京大学首钢医院收治的96例晚期NSCLC患者为研究对象,随机分为吉西他滨+顺铂组(GP组)和培美曲赛+顺铂组(AP组),每组48例,GP组给予吉西他滨+顺铂化疗,AP组给予培美曲赛+顺铂化疗。比较两组患者化疗疗效及肿瘤标志物的变化情况。结果 两组患者化疗后,AP组ORR(29.17%)和DCR(81.25%)均显著高于GP组,比较差异均有统计学意义(P<0.05)。化疗后,GP组与AP组的癌胚抗原水平分别为54.6±7.9、23.5±5.9,CA125分别为87.8±7.2、50.4±8.3。治疗前两组CEA和CA125水平相比差异无有统计学意义,治疗后两组CEA和CA125水平均较治疗前显著下降(P<0.05),治疗后AP组各指标下降程度大于GP组,差异有统计学意义(P<0.05)。结论 给予晚期NSCLC患者AP方案化疗能显著提高临床疗效,且明显降低患者肿瘤标志物的水平,值得推广。

Clinical efficacy of different chemotherapy regimens for advanced non-small cell lung cancer and correlations between tumor markers and efficacy

Objective To investigate the clinical efficacy of different chemotherapy regimens in the treatment of advanced non-small cell lung cancer and the correlations between tumor markers and clinical efficacy.Methods Ninety-six cases of advanced non-small cell lung cancer patients admitted between January 2015 and June 2017 were selected as subjects. They were randomly divided into GP and AP group. GP group was given gemcitabine plus cisplatin chemotherapy, while AP group was given permedusa plus cisplatin chemotherapy. Chemotherapy efficacy and tumor markers were compared between the two groups.Results After chemotherapy, the ORR (29.17%) and DCR (81.25%) in the AP group were significantly higher than those in the GP group (P<0.05). After chemotherapy, the level of cancer embryo antigens in the GP group and AP group was 54.6±7.9 and 23.5±5.9 respectively, while CA125 was 87.8±7.2 and 50.4±8.3 respectively. Before treatment, CEA and CA125 levels of the two groups were not statistically significant, but were significantly different after treatment (P<0.05). After treatment, the index of the AP group was decreased more significantly than in GP group, and the difference was statistically significant (P<0.05).Conclusions AP chemotherapy can significantly improve the clinical efficacy of patients with advanced non-small cell lung cancer, and reduce the level of tumor markers. It is worth promoting.